News & Updates
Filter by Specialty:
Adjuvant atezolizumab improves DFS in early-stage NSCLC
In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression ≥1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.
Adjuvant atezolizumab improves DFS in early-stage NSCLC
27 Oct 2021
Helmet-CPAP safely improves oxygenation in pregnant women with COVID-19 respiratory failure
Administrating continuous positive airway pressure (CPAP) through a helmet (h-CPAP) device safely improves oxygenation in women with moderate-to-severe acute respiratory failure (ARF) due to the coronavirus disease 2019 (COVID-19), a recent study has found.
Helmet-CPAP safely improves oxygenation in pregnant women with COVID-19 respiratory failure
27 Oct 2021
Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.
Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
26 Oct 2021
Kids hard-hit by Delta; which ART performs best?
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
